Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection
RSC Pharmaceutics · 2026 · 3 (4) · 1022-1033
DOI: 10.1039/d5pm00380f ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Connor T Murphy und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC Chapel Hill NC USA ainsliek@email.unc.edu. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
A novel, mast cell activating small molecule was combined with the FDA-approved adjuvant, CpG, to produce an effective dual-adjuvanted mucosal vaccine formulation for orthopoxviruses.
Autor:innen und Institutionen
- Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC Chapel Hill NC USA ainsliek@email.unc.edu.
- Department of Pathology, Duke University Durham NC USA.
- Department of Chemistry, Duke University Durham NC USA.
- Department of Biomedical Engineering, NC State/UNC Chapel Hill NC USA.
- Carborro High School Chapel Hill NC USA.
- Department of Pathology & Laboratory Medicine, School of Medicine, UNC Chapel Hill NC USA.
ORCID-Profile: Kristy M Ainslie
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
- National Cancer Institute
- National Science Foundation
- Division of Microbiology and Infectious Diseases
Zitieren
APA
Murphy, C. T., Williamson, G. L., Ontiveros-Padilla, L., Hendricksen, A. T., Johnson-Weaver, B. T., Choi, H. W., Gooden, D. M., Kalpathy, S., Lopez, A. M., Pena, E. S., Bachelder, J. M., Sellers, R. S., Abraham, S. N., Staats, H. F., & Ainslie, K. M. (2026). Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection. RSC Pharmaceutics, 3(4), 1022-1033. https://doi.org/10.1039/d5pm00380f
Vancouver
Murphy CT, Williamson GL, Ontiveros-Padilla L, Hendricksen AT, Johnson-Weaver BT, Choi HW, et al. Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection. RSC Pharmaceutics. 2026;3(4):1022-1033. doi:10.1039/d5pm00380f
BibTeX
@article{Murphy2026,
author = {Murphy, Connor T and Williamson, Grace L and Ontiveros-Padilla, Luis and Hendricksen, Aaron T and Johnson-Weaver, Brandi T and Choi, Hae Woong and Gooden, David M and Kalpathy, Santhosh and Lopez, Alexandra M and Pena, Erik S and Bachelder, Jacob M and Sellers, Rani S and Abraham, Soman N and Staats, Herman F and Ainslie, Kristy M},
title = {Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection},
journal = {RSC Pharmaceutics},
year = {2026},
volume = {3},
number = {4},
pages = {1022--1033},
doi = {10.1039/d5pm00380f}
}
EUVIMED